
    
      The maximum tolerated dose (MTD) and pharmacokinetics of a new formulation of taxane
      (liposomal paclitaxel) have never been studied in Chinese cancer patients, either alone or
      with capecitabine .This clinical trial is designed to find out the MTD and pharmacokinetics
      of liposomal paclitaxel with a beginning dose of 175mg/m2 with/without Capecitabine in
      Chinese patients with advanced gastric carcinoma.
    
  